Should methylphenidate and hydroxychloroquine be continued in a patient with acute influenza?

Management of Methylphenidate and Hydroxychloroquine During Acute Influenza

Both methylphenidate and hydroxychloroquine can generally be continued during acute influenza illness, with specific monitoring considerations for each medication.

Methylphenidate Management

Continue methylphenidate during uncomplicated influenza in most patients, but temporarily discontinue if the patient develops severe illness requiring hospitalization or has significant cardiovascular instability.

Clinical Decision Algorithm:

• Mild-to-moderate influenza (outpatient): Continue methylphenidate at current dose

  • Monitor for tachycardia and hypertension, which may be additive with influenza-related fever 1
  • Ensure adequate hydration, as both influenza and methylphenidate can affect fluid status
  • The FDA label emphasizes monitoring blood pressure and heart rate during methylphenidate therapy 1

• Severe influenza requiring hospitalization: Consider temporary discontinuation

  • If patient meets ≥2 unstable clinical factors (temperature >37.8°C, heart rate >100/min, respiratory rate >24/min, systolic BP <90 mmHg, oxygen saturation <90%, inability to maintain oral intake, abnormal mental status) 2
  • Methylphenidate increases blood pressure (mean 2-4 mmHg) and heart rate (mean 3-6 bpm), which may complicate management of severe influenza 1
  • Resume once patient is clinically stable and able to maintain oral intake

Important Considerations:

Interestingly, research suggests that longer-term methylphenidate use (≥90 days) is associated with a 38% reduction in influenza risk in children and adolescents with ADHD (HR 0.62,95% CI 0.52-0.75), possibly due to improved medication compliance and behavioral adherence 3. This protective effect was not seen with shorter treatment durations.

Hydroxychloroquine Management

Continue hydroxychloroquine during acute influenza without modification in patients taking it for rheumatologic conditions.

Rationale:

• Hydroxychloroquine has no proven efficacy against influenza 4, 5

  • A large randomized controlled trial (n=1,516) showed chloroquine did not prevent influenza infection (RR 1.34,95% CI 0.83-2.14) 5
  • Long-term hydroxychloroquine use provides no protective effect against influenza in patients with rheumatoid arthritis or systemic lupus erythematosus 4

• Stopping hydroxychloroquine risks disease flare of the underlying rheumatologic condition

  • Influenza vaccination remains safe and reasonably effective in SLE patients on hydroxychloroquine 6
  • The underlying disease (e.g., lupus) poses greater risk than continuing the medication

Critical Safety Warning:

Avoid combining hydroxychloroquine with oseltamivir if possible, as this combination significantly increases risk of critical QTc prolongation (OR 5.3,95% CI 1.02-28) 7. If both medications are necessary:

• Obtain baseline and follow-up ECGs
• Monitor for QTc >500 ms or increase >60 ms from baseline
• This is particularly important during influenza season when oseltamivir may be prescribed

Influenza Treatment Recommendations

Regardless of decisions about chronic medications, appropriate influenza management includes:

• Antiviral therapy (oseltamivir 75 mg twice daily for 5 days) for patients who are hospitalized, have severe/progressive illness, or are at high risk of complications 8, 9
• Start antivirals as soon as possible, ideally within 48 hours of symptom onset 2
• Antibiotics only if bacterial coinfection is suspected (recrudescent fever, increasing dyspnea, extensive pneumonia) 2, 8

Common Pitfalls to Avoid

1. Do not routinely discontinue chronic medications during mild influenza—the risk of disease destabilization often exceeds any theoretical benefit
2. Do not use hydroxychloroquine to treat or prevent influenza—it is ineffective and may cause unnecessary side effects
3. Do not combine hydroxychloroquine with oseltamivir without ECG monitoring due to additive QTc prolongation risk
4. Do not withhold methylphenidate based solely on fever—tachycardia from fever alone is not a contraindication unless accompanied by cardiovascular instability